M&A

News

Lilly has continued its lengthy streak of acquisitions in 2026 with a $2.88 billion agreement to buy immunology and inflammation specialist Merida.

News

BioMarin will acquire Alesta's experimental therapy for rare bone disease hypophosphatasia for up to $490 million.

News

Following the failure of its sickle cell programme, Fulcrum Therapeutics will merge with Slate Medicines to advance Slate's migraine therapy.

News

A year after its $9.1bn acquisition of Blueprint Medicines, Sanofi is moving out of Blueprint's Cambridge, MA offices and letting 229 employees go.

News

Jazz Pharma has dipped its toe into the M&A water again, agreeing to buy rare epilepsy drug developer Actio Bio for $820m upfront.

Sales & Marketing

The diagnostics and life sciences tools sector is attracting continued investor interest across both private equity and large corporates.